Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer

Journal of Clinical Oncology

Volumn 25, Issue 4, 2007, Pages 347-348

  Lilja, Hans ^a   Vickers, Andrew ^a   Scardino, Peter ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; MOLECULAR MARKER; PLASMA PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; TRYPSIN; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; TUMOR MARKER; UNCLASSIFIED DRUG;

BLOOD COMPONENT; CANCER RISK; CANCER STAGING; EDITORIAL; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEASUREMENT; OUTCOME ASSESSMENT; PEPTIDOMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; RISK; BLOOD; MALE; NOTE; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 33847004756     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.5035     Document Type: Editorial

References (26)

1. Stenman U, Abrahamsson P, Aug G, et al: Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol 216:64-81, 2005 (suppl)
2. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985
3. Steuber T, Vickers AJ, Haese A, et al: Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 118:1234-1240, 2006
4. Stephan C, Xu C, Brown DA, et al: Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate 66:651-659, 2006
5. Villanueva J, Shaffer DR, Philip J, et al: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284, 2006
6. Danø K, Behrendt N, Brünner N, et al: The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:189-203, 1994
7. Laufs S, Schumacher J, Allgayer H: Urokinase receptor (u-PAR): An essential player in multiple games of cancer: A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5:1760-1771, 2006
8. Norton L, Massagué J: Is cancer a disease of self-seeding? Nat Med 12:875-878, 2006
9. Behrendt N, List K, Andreasen PA, et al: The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: Rescue of activity through reciprocal pro-enzyme activation. Biochem J 371:277-287, 2003 (part 2)
10. Stephens RW, Pollanen J, Tapiovaara H, et al: Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 108:1987-1995, 1989
11. Behrendt N, Rønne E, Danø K: Domain interplay in the urokinase receptor: Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 271:22885-22894, 1996
12. Høyer-Hansen G, Behrendt N, Ploug M, et al: The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Lett 420:79-85, 1997
13. Høyer-Hansen G, Rønne E, Solberg H, et al: Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267:18224-18229, 1992
14. Wilhelm OG, Wilhelm S, Escott GM, et al: Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 180:225-235, 1999
15. Rønne E, Pappot H, Grøndahl-Hansen J, et al: The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 89:576-581, 1995
16. Pappot H, Høyer-Hansen G, Rønne E, et al: Elevated plasma levels of urokinase plasminogen activator in non-small cell lung cancer. Eur J Cancer 33:867-872, 1997
17. Stephens RW, Pedersen AN, Nielsen HJ, et al: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-1876, 1997
18. Riisbro R, Christensen IJ, Piironen T, et al: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumour tissue from patients with primary breast cancer. Clin Cancer Res 8:1132-1141, 2002
19. Wahlberg K, Høyer-Hansen G, Casslén B: Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentrations in cystic fluid from ovarian cancer. Cancer Res 58:3294-3298, 1998
20. Stephens RW, Nielsen HJ, Christensen IJ, et al: Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 91:869-874, 1999
21. Linja MJ, Savinainen KJ, Saramäki OR, et al: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555, 2001
22. Cozzi PJ, Wang J, Delprado W, et al: Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 37:1442-1451, 2006
23. Piironen T, Haese A, Huland H, et al: Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 52:838-844, 2006
24. Shariat SF, Roehrborn CG, McConnell JD, et al: Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25:349-355, 2007
25. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499-1507, 1999
26. Piironen T, Laursen B, Pass J, et al: Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 50:2059-2068, 2004